Allergan Buys Dermatology Product

Irvine-based Allergan said Monday that it has entered into an agreement with QLT USA, to purchase the firm's Aczone (dapsone) Gel 5% product, a topical treatment for acne vulgaris. Allergan said it will pay approximately $150M for all assets related to the product, which it said could reach revenues in excess of $75M per year. Aczone is used for treating acne; the product is expected to launch in Q4 of this year. Allergan is a supplier of pharmaceuticals and other health care products.